Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population

• Published in: Liver international 2020-04, Vol.40 (4), p.787-796
• Main Authors: Schmidbauer, Caroline, Chromy, David, Schmidbauer, Victor, Bauer, David, Apata, Michael, Nguyen, Dung, Mandorfer, Mattias, Simbrunner, Benedikt, Rieger, Armin, Mayer, Florian, Schmidt, Ralf, Holzmann, Heidemarie, Trauner, Michael, Gschwantler, Michael, Reiberger, Thomas
• Format: Article
• Language: English
• Subjects: Confidence intervals; Epidemiology; Eradication; Hepatitis; Hepatitis C; Hepatitis C virus; HIV; Human immunodeficiency virus; Infections; MSM; Original; PWIDs; Ribonucleic acid; Risk taking; RNA; Sexual behavior; Sexually transmitted diseases; STD; Trends; Viral Hepatitis; Viremia; Viruses
• ISSN: 1478-3223; 1478-3231
• DOI: 10.1111/liv.14399

Background & Aims Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection is common in people who inject drugs (PWIDs). Recently, ‘high‐risk’ behaviour among men who have sex with men (MSM) has emerged as another main route of HCV transmission. We analysed temporal trends in HCV epidemiology in a cohort of Viennese HIV+ patients. Methods Hepatitis C virus parameters were recorded at HIV diagnosis (baseline [BL]) and last visit (follow‐up [FU]) for all HIV+ patients attending our HIV clinic between January 2014 and December 2016. Proportions of HIV+ patients with anti‐HCV(+) and HCV viraemia (HCV‐RNA(+)) at BL/FU were assessed and stratified by route of transmission. Results In all, 1806/1874 (96.4%) HIV+ patients were tested for HCV at BL. Anti‐HCV(+) was detected in 93.2% (276/296) of PWIDs and in 3.7% (31/839) of MSM. After a median FU of 6.9 years, 1644 (91.0%) patients underwent FU HCV‐testing: 167 (90.3%) of PWIDs and 49 (6.7%) of MSM showed anti‐HCV(+). Among 208 viraemic HCV‐RNA(+) patients at BL, 30 (14.4%) had spontaneously cleared HCV, 76 (36.5%) achieved treatment‐induced eradication and 89 (42.8%) remained HCV‐RNA(+) at last FU. Among 1433 initially HCV‐naive patients, 45 (3.5%) acquired de‐novo HCV infection (11.1% PWIDs/80.0% MSM; incidence rate (IR) 0.004%; 95% confidence interval [CI] 0.0%‐0.022%) and 14 had HCV reinfections (85.7% PWIDs/14.3% other; IR 0.001%; 95% CI 0.0%‐0.018%) during a median FU of 6.7 years (interquartile range 7.4). Conclusion Hepatitis C virus testing was successfully implemented in the Viennese HIV(+) patients. Anti‐HCV(+) prevalence remained stable in HIV+ PWIDs but almost doubled in HIV+ MSM. De‐novo HCV infection occurred mostly in MSM, while HCV reinfections were mainly observed in PWIDs. HCV treatment uptake was suboptimal with 42.8% remaining HCV‐RNA(+) at FU.